Anthropic Says Mithril Drug Reached Animal Testing With AI Support

Anthropic said its acquired drug developer Mithril Medicine has advanced a potential treatment for a rare muscle-wasting disease to animal testing, after using the company’s AI tools to coordinate research across outside laboratories. The company disclosed partnerships with six biomedical organizations in October and acquired Mithril, which had one full-time employee. Mithril’s founder used Claude to manage experiments, analyze data and coordinate work at 11 outside labs. The research reached animal testing in less than 18 months. Some treated mice showed about twice the grip and muscle strength of untreated mice, and their survival improved. Anthropic said the treatment could enter human trials as early as late 2028 if further experiments go well. That timing remains conditional on the results of those experiments.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.